Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases.

Pharmaceutical

Novo Nordisk

Thomas Rantzau is a member of the Board at [Novo Nordisk](/org/novo-nordisk). Thomas has previously worked for Chr. Hansen A/S, [Novo Nordisk](/org/novo-nordisk), and [Novo Nordisk](/org/novo-nordisk) A/S. Rantzau has been in their current position since January 1996.

Thomas Rantzau's educational career consists of studying to be a Mejerist at Den Kgl. Veterinær- og Landbohøjskole and Dalum tekniske Skole.

Thomas Rantzau

Tina Abild Olesen is the Senior Vice President Global Commercial Strategy at [Novo Nordisk](/org/novo-nordisk). Tina has over 20 years of experience in the pharmaceutical industry. Tina started their career at GSK in September 1997 as a Business Unit Director. Tina held this position for 12 years before moving to [Novo Nordisk](/org/novo-nordisk) in February 2009.

Tina Abild Olesen has a M. Sc. in Economics & Business Administration from [Copenhagen Business School](/org/copenhagen-business-school), an MBA from [INSEAD](/org/insead), and a Master's degree in Business Administration from [Harvard University](/org/harvard). Tina also has a diploma in Strategic Leadership from Henley Business School and a degree in Organizational Behaviour from [Nottingham Trent University](/org/nottingham-trent-university).

They work with and Jan Hoff - Senior Vice President Commercial Business Development. Tina Abild Olesen reports to Camilla Sylvest, EVP Commercial Strategy & Corporate Affairs.

Tina Abild Olesen

Karin began their pharmaceutical career at Johnson and Johnson in September of 2013 as Vice President for Cardiovascular and Metabolism. In this role, Karin was responsible for identifying, establishing, and managing external scientific opportunities for early research through clinical POCs in the area of cardiovascular and metabolism.

In April of 2010, Karin took on the role of Acting Head of Discovery for Roche. In this role, they were responsible for all discovery efforts in the cardiovascular and metabolism DTA. Karin was with Roche for just over three years before moving on to their current position at [Novo Nordisk](/org/novo-nordisk).

Karin is currently Senior Vice President of Global Drug Discovery at [Novo Nordisk](/org/novo-nordisk). In this role, they are responsible for leading the global drug discovery organization and strategies across all [Novo Nordisk](/org/novo-nordisk) R&D sites.

Karin Conde-Knape is a post-doctoral researcher in the field of lipids and lipoproteins at Columbia University Vagelos College of Physicians and Surgeons. Karin holds a PhD from the [University of Connecticut](/org/university-of-connecticut).

Karin Conde-Knape reports to Marcus Schindler, EVP for Research and Early Development & Chief Scientific Officer. A direct report to Karin Conde-Knape is and Mads Tang-Christensen - CVP, Therapeutic Area Head Global Obesity & Liver Disease Research. They are on a team with Rasmus Rabøl - Corporate Vice President, Translational Science and Medicine, Anette Spahn Klausen - EVP Communication Partner, and Jesper Bøving - Senior Vice President CMC.

Karin Conde-Knape

Robin Evers is the Senior Vice President at [Novo Nordisk](/org/novo-nordisk). Robin has over 25 years of experience in the pharmaceutical industry, having started their career at [Pfizer](/org/pfizer) in 1994. Robin has held various positions at [Pfizer](/org/pfizer), including Vice President - Regulatory and Vice President, Worldwide Regulatory Strategy. In 2010, they joined [Novo Nordisk](/org/novo-nordisk) as Senior Vice President.

Evers has a Bachelor of Science in Pharmacy from the [University of Minnesota](/org/university-of-minnesota) and a MBA from [Rutgers University](/org/rutgers-university).

Robin Evers studied management studies at the [University of Reading](/org/university-of-reading) and earned a Bachelor of Science in molecular biology from the [University of Portsmouth](/org/university-of-portsmouth).

Robin Evers reports to Martin Holst Lange, EVP, Head of Development. Robin Evers works with Stephen Gough - Global Chief Medical Officer, Kenneth Strømdahl - Senior Vice President, Device R&D.

Robin Evers

Anja Jørgensen is the Senior Vice President Device and Supply Chain at [Novo Nordisk](/org/novo-nordisk). Anja has over twenty years of experience in management consulting and has worked with some of the world's largest organizations. Prior to joining [Novo Nordisk](/org/novo-nordisk), they were with [Accenture](/org/accenture) for nearly ten years, where they rose to the position of Management Consultant.

Anja Jørgensen attended [Copenhagen Business School](/org/copenhagen-business-school), where they earned a degree in business administration.

They work with Preben Haaning - Senior Vice President, Flemming Dahl - Head of Quality, Senior Vice President, and Jean Fabian Jeldorf - Senior Vice President. Anja Jørgensen reports to Henrik Wulff, Executive Vice President, Product Supply, Quality & IT.

Anja Jørgensen

Flemming Dahl is currently the Head of Quality and Senior Vice President at [Novo Nordisk](/org/novo-nordisk). Prior to this, they served as Senior Vice President at [Novo Nordisk](/org/novo-nordisk) from June 1994 to January 2015, where they were responsible for a large Production unit producing Biopharmaceuticals products. Dahl has also previously worked as a Plant Engineer at [Kuwait Petroleum Corporation](/org/kuwait-petroleum-corporation) from November 1991 to May 1994.

Flemming Dahl has a board certificate from Board Assure in strategic leadership and a degree in chemistry from the Technical University of Denmark. Flemming also attended Struer Gymnasium, where they studied mathematics and physics.

Flemming Dahl reports to Henrik Wulff, Executive Vice President, Product Supply, Quality & IT. They are on a team with Preben Haaning - Senior Vice President, Louise Bondo - QA professional, and Anja Jørgensen - Senior Vice President Device and Supply Chain.

Flemming Dahl

Jean Fabian Jeldorf is the Senior Vice President at [Novo Nordisk](/org/novo-nordisk). Jean has been with the company since December of 2002 and has held various positions including Vice President of Product Supply Finance. Prior to their time at [Novo Nordisk](/org/novo-nordisk), Jean Fabian worked as an auditor for [Deloitte](/org/deloitte) from 1996 to 1999. Afterward, they became the financial controller for ATP before moving on to Ernst & Young in 2000 where they worked as a manager until 2002.

Jean Fabian Jeldorf has a MSc in business economics and auditing from [Copenhagen Business School](/org/copenhagen-business-school). Jean also has a degree from Høje Taastrup Gymnasium.

Jean Fabian Jeldorf reports to Henrik Wulff, Executive Vice President, Product Supply, Quality & IT. They work with Susanne Hundsbæk-Pedersen - Senior Vice President, Devices & Supply Chain Management, Anders Romare - CIO & Senior Vice President Global IT, and Anja Jørgensen - Senior Vice President Device and Supply Chain.

Jean Fabian Jeldorf

Preben Haaning is the Senior Vice President at [Novo Nordisk](/org/novo-nordisk). Preben has also worked as the [Novo Nordisk](/org/novo-nordisk) Haemophilia Foundation and as a Platoon Leader for the [United Nations](/org/united-nations). Preben Haaning has also worked as a First Lieutenant for the Danish Army.

Preben Haaning took A-levels in commerce at Niels Brock before completing A-levels at Roskilde Katedral skole. Preben then attended Fløng Skole. After that, they earned a Graduate Diploma in Business Administration with a focus in Organizational Development (HD-O) from [Copenhagen Business School](/org/copenhagen-business-school). Preben Haaning is also an engineer, having studied industrial engineering at Copenhagen University College of Engineering. Lastly, they are a First Lieutenant in the Danish Army.

Preben Haaning reports to Henrik Wulff, Executive Vice President, Product Supply, Quality & IT. They are on a team with Flemming Dahl - Head of Quality, Senior Vice President, Louise Bondo - QA professional, and Anders Romare - CIO & Senior Vice President Global IT.

Preben Haaning

Anders Romare is the current CIO and Senior Vice President of Global IT at [Novo Nordisk](/org/novo-nordisk). Prior to this, they spent 9 years at Airbus, where they were most recently the Vice President of Technology Services for the Digital Transformation Office. In this role, they were responsible for providing technology services to 150,000 internal users and 50,000 users in the supply chain spread across 600 locations worldwide. This included managing the full life-cycle of major technology backbones such as the digital workplace, helpdesk, network, identity and access management, security operating centre, and hosting (data centre, public/private cloud), as well as SAP platforms.

Under Romare's leadership, the organization underwent a transformation into an agile, business value-driven organization based on product teams. This entailed a shift to new agile ways of working and accelerated the use of new digital technologies such as cloud computing and DevOps. Key achievements during their time at Airbus include successfully executing this organizational transformation and delivering strong results despite a challenging budget environment.

Anders Romare has a non-executive director program from [INSEAD](/org/insead), an executive MBA from the School of Business, Economics and Law at the University of Gothenburg, and an MSc in Electronics from Chalmers University of Technology. Anders also has certification from [INSEAD](/org/insead) Executive Education in Aspiring Directors Programme.

Anders Romare works with Susanne Hundsbæk-Pedersen - Senior Vice President, Devices & Supply Chain Management, Michael Hallgren - Senior Vice President1, and Flemming Dahl - Head of Quality, Senior Vice President. Anders Romare reports to Henrik Wulff, Executive Vice President, Product Supply, Quality & IT.

Anders Romare

Kim Bundegaard is the current Senior Vice President at [Novo Nordisk](/org/novo-nordisk). Kim has been with the company since January 1999 and in their current role since December 2019. Prior to that, they served as the SVP of Business Assurance, Chief Compliance Officer and Data Protection Officer. In that role, they were responsible for overall internal audit (financial, business ethics and IT audits), business ethics compliance, facilitation (values audits), Audit Committee Secretariat including the Compliance Hotline and the Ombudsman function. The function consisted of approximately 60 employees in Denmark and abroad in addition to approximately 100 employees worldwide dealing with various kinds of compliance and assurance activities including responsibility for organizing Audit Committee and relations to the external auditors.

Before joining [Novo Nordisk](/org/novo-nordisk), Kim Bundegaard was an Audit Senior Manager at PricewaterhouseCoopers from January 1989 to December 1999.

Their manager is Karsten Munk Knudsen, Executive Vice President, Chief Financial Officer. They are on a team with Peter Bøggild - Senior Vice President, Business Finance, Tomas Haagen - Group General Counsel & Senior Vice President.

Kim Bundegaard

Thomas Sohns is currently the Corporate Vice President, People & Organisation at [Novo Nordisk](/org/novo-nordisk). Thomas has previously worked as the Director People & Organisation for [Novo Nordisk](/org/novo-nordisk) Business Area Europe North & Central from January 2003 to November 2016 and as the Corporate Vice President, People & Organisation for [Novo Nordisk](/org/novo-nordisk) International Operations from December 2016 to December 2018. Thomas has also worked as the Vicekontochef for Koebenhavns kommune from January 1997 to December 2000.

Thomas Sohns has a Master of Laws from Københavns Universitet - University of Copenhagen and a Master of law from Lyngby Private skole.

Thomas Sohns reports to Monique Carter, EVP & Head of People & Organisation. They work with Julie Rehoff Hansen - Vice President and head of Diversity & Inclusion, Mille Borchorst - SVP People & Organization Business Partnering.

Thomas Sohns

Steve Albers is currently the Corporate Vice President of Market Access & Public Affairs at [Novo Nordisk](/org/novo-nordisk). Steve has been with the company since May 2009, and in their current role, they are responsible for leading [Novo Nordisk](/org/novo-nordisk)'s efforts to expand patient access to its products and ensure a positive public image. Prior to their current role, Steve served as Vice President of Global Market Access at [Novo Nordisk](/org/novo-nordisk) A/S, where they were responsible for leading the company's efforts to gain reimbursement for its products from government and private payers around the world.

Before joining [Novo Nordisk](/org/novo-nordisk), Steve worked for Takeda Pharmaceutical Company Ltd as a District Sales Manager, where they were responsible for sales and marketing initiatives in the Midwest United States. Steve began their career in the pharmaceutical industry as a Medical Sales Representative for Mead Johnson Nutritionals.

Steve holds a Bachelor's degree in Biology from the [University of Notre Dame](/org/university-of-notre-dame).

Steve Albers attended [Concordia College](/org/concordia-college), where they earned a Bachelor of Arts in Biology/Biological Sciences, General.

Steve Albers reports to Doug Langa, Executive Vice President, North America Operations. They are on a team with Anne Phillips - Senior Vice President, Clinical, Medical and Regulatory Affairs US, Pia D'Urbano - Corporate Vice President, and Ulrich Otte - Senior Vice President Finance & Operations.

Steve Albers

Anne Phillips is the Senior Vice President of Clinical, Medical and Regulatory Affairs at [Novo Nordisk](/org/novo-nordisk). Prior to joining [Novo Nordisk](/org/novo-nordisk), Anne served as the Vice President of MDL at GlaxoSmithKline from 1998 to 2010. Before their time at GlaxoSmithKline, Anne was the Medical Director at Casey House Foundation from 1994 to 1996. Anne began their career as the Chief of Infectious Diseases at the University of Toronto's Wellesley Central Hospital from 1992 to 1998. Anne has also served as the Director of Microbiology and Infectious Diseases at University Health Network from 1986 to 1992.

Anne Phillips has a Doctor of Medicine from the University of Toronto, and also holds an Hons BSC from [Western University](/org/western-university). Anne has furthered their education at [Stanford University](/org/stanford)'s Graduate School of Business, as well as the MIT Sloan School of Management and [Harvard Business School](/org/harvard-business-school). Anne is currently completing their education at [Queen's University](/org/queens-university).

Anne Phillips reports to Doug Langa, Executive Vice President, North America Operations. Anne Phillips works with Pia D'Urbano - Corporate Vice President, Steve Albers - Corporate Vice President, Market Access & Public Affairs, and Ulrich Otte - Senior Vice President Finance & Operations.

Anne Phillips

Claus Steensen Sølje is the Senior Vice President, Finance, Procurement, IT & Supply Chain, International Operations at [Novo Nordisk](/org/novo-nordisk). Prior to this role, they were the Director - Finance, Logistic, IT & Administration, France & Belgium/Luxembourg. Claus has also worked as a management consultant and economist for various organizations. Claus is currently a member of the board for Industrial Symbiosis.

Claus Steensen Sølje has an MSc in Economics from Københavns Universitet - University of Copenhagen, and also did a summer school at The London School of Economics and Political Science (LSE). Claus also has an MSc from [INSEAD](/org/insead), and has done programs on strategy execution and board performance from Harvard Business School Executive Education and IMD respectively.

Some of their coworkers include Sebnem Avşar Tuna - Senior Vice President Region APAC, Matt Regan - SVP - Head of South & East Europe, Middle East & Africa, and Ole Mølskov Bech - Senior Vice President, [Novo Nordisk](/org/novo-nordisk) Japan. Claus Steensen Sølje reports to Maziar Mike Doustdar, Executive Vice President, International Operations.

Claus Steensen Sølje

Jesper Wenzel Larsen is the current Senior Vice President & General Manager of Germany at [Novo Nordisk](/org/novo-nordisk). Jesper has been with the company since January 2002 and in their current role since December 2014. Prior to that, they served as the General Manager of [Novo Nordisk](/org/novo-nordisk) Pharma Switzerland from January 1992 to December 2001. Jesper also held the position of Finance & Administration Manager for [Novo Nordisk](/org/novo-nordisk) Switzerland/Germany during that time.

Jesper Wenzel Larsen completed a strategy execution program at [Harvard Business School](/org/harvard-business-school), a high performance leadership program at IMD in Switzerland, and a Programme for Executive Development at IMD in Switzerland. Jesper also holds an MSc in Economics and Business Administration from [Copenhagen Business School](/org/copenhagen-business-school) in Denmark.

Their manager is Maziar Mike Doustdar, Executive Vice President, International Operations. Some of their coworkers include Matt Regan - SVP - Head of South & East Europe, Middle East & Africa, Frederik Kier - Senior Vice President, North West Europe, and Ole Mølskov Bech - Senior Vice President, [Novo Nordisk](/org/novo-nordisk) Japan.

Jesper Wenzel Larsen

Matt Regan is the SVP - Head of South & East Europe, Middle East & Africa at [Novo Nordisk](/org/novo-nordisk). Matt has been with the company since May 2017 and has been instrumental in turning around the business and gaining market share. Prior to joining [Novo Nordisk](/org/novo-nordisk), Matt was the VP & General Manager - UK, AbbVie Pharmaceuticals where they led the company to becoming the best place to work in Pharma in 2015.

Matt Regan has an Executive MBA in Finance and Strategy from the [National University of Ireland, Galway](/org/national-university-of-ireland-galway), as well as a BSc in Polymer Engineering with 1st Class honours from [Athlone Institute of Technology](/org/athlone-institute-of-technology).

Some of their coworkers include Andrzej Popkowski - Senior Vice President, LATAM, Claus Steensen Sølje - Senior Vice President, Finance, Procurement, IT & Supply Chain, International Operations, and Ole Mølskov Bech - Senior Vice President, [Novo Nordisk](/org/novo-nordisk) Japan. Their manager is Maziar Mike Doustdar, Executive Vice President, International Operations.

Matt Regan

Frederik Kier is the Senior Vice President, North West Europe at [Novo Nordisk](/org/novo-nordisk). Prior to this role, Kier was the SVP Europe & Strategic Accounts at GN ReSound from August 2015 to January 2017. From August 2002 to July 2015, Kier held the position of Corporate Vice President, Global Marketing at [Novo Nordisk](/org/novo-nordisk) A/S. Before joining [Novo Nordisk](/org/novo-nordisk), Kier was the CEO Management Assistant at [NNIT](/org/nnit) from January 2000 to July 2002.

Frederik Kier earned a Master of Science in Business Administration degree with a specialization in International Management from Syddansk Universitet - University of Southern Denmark. Frederik also holds a Master of Business Administration (MBA) degree from the [University of Utah](/org/university-of-utah).

They work with Ole Mølskov Bech - Senior Vice President, [Novo Nordisk](/org/novo-nordisk) Japan, Jesper Wenzel Larsen - Senior Vice President & General Manager of Germany, and Andrzej Popkowski - Senior Vice President, LATAM. Frederik Kier reports to Maziar Mike Doustdar, Executive Vice President, International Operations.

Frederik Kier

Christine Zhou is the SVP and President of Region China at [Novo Nordisk](/org/novo-nordisk). Christine has over 20 years of experience in the pharmaceutical industry, including their time at Eli Lilly and Company where they served as SVP and Head of Oncology and BioMedicines, CHINA. Christine is responsible for full P&L of both Oncology and BioMedicines in China, pipeline strategy and advancement, alliance leadership, people engagement and development.

Christine Zhou's educational career began with their studying medicine at Shanghai Medical University. Christine then went on to complete an AMP183 program at Harvard Business School.

They work with Matt Regan - SVP - Head of South & East Europe, Middle East & Africa, Sebnem Avşar Tuna - Senior Vice President Region APAC, and Andrzej Popkowski - Senior Vice President, LATAM. Their manager is Maziar Mike Doustdar, Executive Vice President, International Operations.

Christine Zhou

John McDonald is currently the Corporate Vice President of R&D Business Development at [Novo Nordisk](/org/novo-nordisk). John has previously served as the Vice President of Business Development at [Biogen](/org/biogen) from June 2011 to September 2018, Managing Director at [MPM Capital](/org/mpm-capital) from May 2006 to June 2011, Vice President of Business Development at Millennium Pharmaceuticals from April 2000 to May 2006, Senior Director of Corporate Development at Genzyme from January 1998 to December 2000, and Corporate Counsel at Genentech Inc. from January 1993 to December 1998.

John McDonald has a Bachelor of Business Administration (B.B.A.) from the University of California, Berkeley in Accounting and Finance. John also has a Master of Business Administration (MBA) from the University of California, Berkeley, Haas School of Business in Finance, General. Lastly, they have a Doctor of Law (J.D.) from the University of California, Hastings College of the Law.

John McDonald reports to Marcus Schindler, EVP for Research and Early Development & Chief Scientific Officer. They are on a team with Jacob Sten Petersen - Corporate Vice President, Stem Cell R&D, Tamara Darsow - Corporate Vice President, R&D Strategy and Portfolio Management, and Anette Spahn Klausen - EVP Communication Partner.

John McDonald

Kenneth Strømdahl is the Senior Vice President of Device R&D at [Novo Nordisk](/org/novo-nordisk). Prior to joining [Novo Nordisk](/org/novo-nordisk), Kenneth served in the Danish Army for 16 years, rising to the rank of Captain. Kenneth has also worked as a First Lieutenant in the Danish Army. Kenneth has a long and distinguished career in the military and in the private sector, and they are a highly respected leader in the field of device development.

Kenneth Strømdahl has a program for executive development from IMD, a PhD in structural engineering and materials from DTU - Technical University of Denmark, a PhD in structural engineering and materials from [University of Maine](/org/university-of-maine), an MSc. in engineering from DTU - Technical University of Denmark, and a board certificate from Board Company.

Some of their coworkers include Robin Evers - Senior Vice President, Stephen Gough - Global Chief Medical Officer. Kenneth Strømdahl reports to Martin Holst Lange, EVP, Head of Development.

Kenneth Strømdahl

Jacob Sten Petersen, Corporate Vice President of Stem Cell R&D at [Novo Nordisk](/org/novo-nordisk), is a Danish scientist and businessman with over 25 years of experience in the pharmaceutical industry. Jacob has worked on islet biology/pharmacology and type 1 diabetes intervention/prevention for much of their career. In 2001, they became Department head at [Novo Nordisk](/org/novo-nordisk) Pharmaceuticals and held that position until 2002 when they became Chief Scientific Officer at Inoxell. In 2008, they returned to [Novo Nordisk](/org/novo-nordisk) as Vice President of Research & Development. In their current role, they oversee all stem cell research and development at [Novo Nordisk](/org/novo-nordisk).

Jacob Sten Petersen has a MSc in biochemistry from Københavns Universitet - University of Copenhagen and a DMSc in immunology, autoimmunity, endocrinology and diabetes from the same school.

Jacob Sten Petersen reports to Marcus Schindler, EVP for Research and Early Development & Chief Scientific Officer. They are on a team with Tamara Darsow - Corporate Vice President, R&D Strategy and Portfolio Management, Karin Conde-Knape - Senior Vice President, Global Drug Discovery, and John McDonald - Corporate Vice President, R&D Business Development.

Jacob Sten Petersen

Bridget Lilliehöök is the Senior Director, Executive Assistant to the CSO and EVP, Research and Early Development at [Novo Nordisk](/org/novo-nordisk). Prior to this, they were a Project Manager at [Jabra](/org/jabra) from April 2008 to September 2011. Before that, they were a Project Engineer, Renewable Energy at [Black & Veatch](/org/black-veatch) from May 2007 to December 2007. Lilliehöök began their career as a Research Assistant at the [University of Waterloo](/org/university-of-waterloo), Water Resources Group from May 2005 to December 2005.

Bridget Lilliehöök has a Bachelor of Applied Science (BASc) from the [University of Waterloo](/org/university-of-waterloo), a Bachelor of Arts (BA) from the [University of Waterloo](/org/university-of-waterloo), and an Executive Medical Master of Business Strategy from CBS Executive Fonden. Bridget also has an Executive education from IMD in the field of Advanced Marketers Program.

Some of their coworkers include Lars Fogh Iversen - Senior Vice President, Global Research Technologies, Jacob Sten Petersen - Corporate Vice President, Stem Cell R&D, and Jesper Bøving - Senior Vice President CMC. Bridget Lilliehöök reports to Marcus Schindler, EVP for Research and Early Development & Chief Scientific Officer.

Bridget Lilliehöök

Rasmus Rabøl is currently the corporate vice president of translational science and medicine at [Novo Nordisk](/org/novo-nordisk). Rasmus was previously a postdoctoral fellow at Yale University School of Medicine, where they conducted in vivo human studies on muscular insulin resistance and lipid metabolism in young insulin resistant subjects, as well as rodent studies on the effects of gastric bypass on glucose metabolism. Prior to that, they were a medical advisor at the Danish Medicines Agency, responsible for assessment of risk management plans as rapporteur or co-rapporteur. Rasmus Rabøl also has a PhD from the [University of Copenhagen](/org/university-of-copenhagen), where their thesis was on muscular insulin resistance and mitochondrial function based on interventional studies in patients with type 2 diabetes. Rasmus has also completed fellowships in endocrinology at Hvidovre University Hospital and in internal medicine at Region Zealand.

Rasmus Rabøl completed a Doctor of Medicine (MD) at Københavns Universitet - [University of Copenhagen](/org/university-of-copenhagen) in the field of medicine. Rasmus then pursued a Master's degree in Pharmaceutical Medicine at the [University of Surrey](/org/university-of-surrey). Currently, Rasmus Rabøl is completing their Doctor of Philosophy (PhD) in Type 2 Diabetes and Skeletal Muscle Insulin Resistance at Københavns Universitet - [University of Copenhagen](/org/university-of-copenhagen).

They work with Lars Fogh Iversen - Senior Vice President, Global Research Technologies, Karin Conde-Knape - Senior Vice President, Global Drug Discovery, and Jacob Sten Petersen - Corporate Vice President, Stem Cell R&D. Rasmus Rabøl reports to Marcus Schindler, EVP for Research and Early Development & Chief Scientific Officer.

Rasmus Rabøl

Michael Hallgren is the Senior Vice President1 at [Novo Nordisk](/org/novo-nordisk). Michael has also served as a Board Member of BIOPRO from January 2016 to December 2019, and as Chairman of Kalundborg Symbiosis from January 2015 to December 2021. Prior to their current position, they were the Direktør/ SVP at [Novo Nordisk](/org/novo-nordisk).

Michael Hallgren has a B.Sc. in Mechanical Engineering from DTU - Technical University of Denmark and a B.Sc. in Maskiningeniør from Ingeniør Højskolen Haslev Teknikum. Michael also has a Senior Executive Program 2012 from [London Business School](/org/london-business-school).

Michael Hallgren reports to Henrik Wulff, Executive Vice President, Product Supply, Quality & IT. Some of their coworkers include Louise Bondo - QA professional, Susanne Hundsbæk-Pedersen - Senior Vice President, Devices & Supply Chain Management, and Anders Romare - CIO & Senior Vice President Global IT.

Michael Hallgren

Tamara Darsow is a Corporate Vice President at [Novo Nordisk](/org/novo-nordisk), where they are responsible for Research and Development Strategy and Portfolio Management. Tamara has been with the company since March 2021.

Prior to their current role, Tamara served as the Corporate Vice President of Research and Early Development Strategy and Portfolio at [Novo Nordisk](/org/novo-nordisk) from March 2019 to March 2021. In this role, they were responsible for defining and executing strategies for building a more diverse and scientifically leading pipeline at [Novo Nordisk](/org/novo-nordisk).

From March 2018 to March 2019, Tamara served as the Vice President of R&D Strategy at [Novo Nordisk](/org/novo-nordisk). In this role, they were responsible for developing and executing the company's R&D strategy.

Tamara began their career at the [American Diabetes Association](/org/american-diabetes-association-inc), where they served as the Vice President of Research Programs from January 2011 to February 2017. In this role, they oversaw the association's research programs and was responsible for developing and implementing strategy, setting priorities, and managing budgets.

Tamara Darsow completed their Bachelor of Science in Medical Microbiology and Bacteriology at Montana State University-Bozeman. Tamara then went on to complete their Doctor of Philosophy in Molecular and Cellular Biology at University of California, San Diego.

Some of their coworkers include Karin Conde-Knape - Senior Vice President, Global Drug Discovery, Jesper Bøving - Senior Vice President CMC, and Anette Spahn Klausen - EVP Communication Partner. Tamara Darsow reports to Marcus Schindler, EVP for Research and Early Development & Chief Scientific Officer.

Tamara Darsow

Pia D'Urbano is a corporate vice president at [Novo Nordisk](/org/novo-nordisk). Pia has over 25 years of experience in the pharmaceutical industry. Pia has held positions at [Sanofi](/org/sanofi), [Bristol-Myers Squibb](/org/bristol-myers-squibb), and GlaxoWellcome.

Pia D'Urbano has a Bachelor of Business Administration from [Concordia University](/org/concordia-university) and a Business Administration diploma from Vanier College.

They work with Anne Phillips - Senior Vice President, Clinical, Medical and Regulatory Affairs US, Ulrich Otte - Senior Vice President Finance & Operations, and Steve Albers - Corporate Vice President, Market Access & Public Affairs. Their manager is Doug Langa, Executive Vice President, North America Operations.

Pia D'Urbano

Ulrich Otte is the Senior Vice President of Finance and Operations at [Novo Nordisk](/org/novo-nordisk). 

Ulrich has held this position since 2006, and prior to that they were the Vice President of corporate governance and risk management at [Novo Nordisk](/org/novo-nordisk) from 2000 to 2006. 

Before joining [Novo Nordisk](/org/novo-nordisk), Ulrich Otte was an audit manager at PricewaterhouseCoopers from 1994 to 2000.

Ulrich Otte has a master's degree in business, economics and auditing from [Copenhagen Business School](/org/copenhagen-business-school).

Ulrich Otte reports to Doug Langa, Executive Vice President, North America Operations. They work with Pia D'Urbano - Corporate Vice President, Steve Albers - Corporate Vice President, Market Access & Public Affairs, and Anne Phillips - Senior Vice President, Clinical, Medical and Regulatory Affairs US.

Ulrich Otte

Martin Holst Lange is the EVP, Head of Development at [Novo Nordisk](/org/novo-nordisk). Martin has been with the company since January 2003 and has held various positions including International Medical Officer.

Martin Holst Lange has a PhD in Endocrinology from Københavns Universitet - University of Copenhagen and an MD from the same school. Martin also attended Gammel Hellerup Gymnasium.

Their manager is Lars Fruergaard Jørgensen, President & CEO. Some individuals on their team include Stephen Gough - Global Chief Medical Officer, Robin Evers - Senior Vice President, and Kenneth Strømdahl - Senior Vice President, Device R&D. Martin Holst Lange works with Camilla Sylvest - EVP Commercial Strategy & Corporate Affairs, Maziar Mike Doustdar - Executive Vice President, International Operations, and Monique Carter - EVP & Head of People & Organisation.

Martin Holst Lange

Jan Hoff is currently the Senior Vice President of Commercial Business Development at [Novo Nordisk](/org/novo-nordisk). Prior to this, they worked at [McKinsey & Company](/org/mckinsey-company) from September 2000 to February 2005. During their time there, they were a Jr. Associate and Engagement Manager, working out of both the Copenhagen and New Jersey offices. Her focus was on strategic projects for global companies within the pharmaceutical manufacturing industry.

Jan Hoff has a Master of Science in Operations Research from DTU - Technical University of Denmark and a Management degree from [McGill University](/org/mcgill-university).

They work with and Tina Abild Olesen - Senior Vice President Global Commercial Strategy. Jan Hoff reports to Camilla Sylvest, EVP Commercial Strategy & Corporate Affairs.

Jan Hoff

Andrzej Popkowski has been with [Novo Nordisk](/org/novo-nordisk) since October 2001 and is currently their Senior Vice President for LATAM. Prior to this, they were with The Janssen Pharmaceutical Companies of [Johnson & Johnson](/org/johnson-johnson) from February 1992 to October 2001 where they held the position of Business Unit Manager.

Andrzej Popkowski has a Bachelor's degree in Anthropology from the University of Adam Mickiewicz - Poznan.

They are on a team with Christine Zhou - SVP and President of Region China, Claus Steensen Sølje - Senior Vice President, Finance, Procurement, IT & Supply Chain, International Operations, and Frederik Kier - Senior Vice President, North West Europe. Andrzej Popkowski reports to Maziar Mike Doustdar, Executive Vice President, International Operations.

Andrzej Popkowski

Ed Baldwin

Joseph Polex-Wolf

Mike  Jacobus

Maria Skjoldborg

Jignesh Patel

Christine  Møller-Jensen

Monique Carter joined [Novo Nordisk](/org/novo-nordisk) in November 2018 as SVP for Global People and Organization and was promoted to executive vice president in August 2019.

Prior to joining [Novo Nordisk](/org/novo-nordisk) Ms Carter was Group HR Director and member of the Executive committee at GKN plc, UK. Ms Carter was at GKN plc from 2014 to 2018.

Ms Carter worked in the chemicals industry from 2005 to 2014 starting with ICI plc, UK (which later became part of Akzo Nobel, the Netherlands). Ms Carter later moved to Singapore to head up the APAC Regional HR while in the Decorative paints division of ICI plc. In 2010 Ms Carter became leading HR for the specialty chemicals businesses of [AkzoNobel](/org/akzonobel) in the Netherlands after the acquisition of ICI plc by Akzo Nobel.

Prior to ICI plc, Ms Carter held HR positions in a number of international companies.

Ms Carter holds a Bachelors degree in Business and Psychology and a postgraduate education in Human Resource Management from the [University of East Anglia](/org/university-of-east-anglia) in the UK. She is a chartered member of the Chartered institute of Personnel and Development in the UK and a member of the British Psychological Society, UK.

Ms Carter is both a British and Irish national, born December 1973.

Monique Carter

Mr Helfgott joined [Novo Nordisk](/org/novo-nordisk) from [AstraZeneca](/org/astrazeneca), where he was global vice president in charge of the company's Cardiovascular, Metabolism and Renal global franchise, supervising both assets in development and on the market. He joined [AstraZeneca](/org/astrazeneca) in 2005 in an international sales effectiveness role and has since held operational leadership roles with increasing responsibilities in Italy, Spain and at corporate headquarters. Prior to this, Mr Helfgott was with [McKinsey & Company](/org/mckinsey-company), in Paris, Moscow and Brussels from 1998 to 2005.

Mr Helfgott holds an M.B.A. from Insead, France, 2001, and is a graduate of the French Army Officer’s Academy, E.A.A.B.C, France, 1998. Moreover, Mr Helfgott holds an M.A. in Finance & Laureate of the Health Economy Chair, E.S.S.E.C, France, 1996, and an M.A. in Political and Macroeconomy, I.E.P. Paris, France, 1994.

Ludovic Helfgott

Mr Doustdar joined [Novo Nordisk](/org/novo-nordisk) in 1992 as an office clerk in Vienna, Austria. From 1993 through 2007 he took up various positions in finance, IT, logistics, operations and marketing, within various parts of [Novo Nordisk](/org/novo-nordisk)’s emerging markets, first in Vienna and subsequently in Athens and Zurich before he was appointed general manager of [Novo Nordisk](/org/novo-nordisk) Near East, based in Turkey, in 2007. In 2010 Mr Doustdar was promoted to vice president of Business Area Near East and in 2012 he re-located to Malaysia to head the Business Area Oceania South East Asia. In 2013 he was promoted to senior vice president of [Novo Nordisk](/org/novo-nordisk)’s International Operations, and in April 2015 Mr Doustdar was promoted to executive vice president, continuing his responsibility for [Novo Nordisk](/org/novo-nordisk)’s International Operations. 

In September 2016 Mike Doustdar assumed additional geographical responsibility and was promoted to executive vice president for an expanded International Operations, leading all commercial units globally, except for USA and Canada.

Maziar Mike Doustdar

Mr Langa joined [Novo Nordisk](/org/novo-nordisk) in 2011 as senior director of Managed Markets. In 2015 Mr Langa was promoted to corporate vice president of Market Access in the US and in 2016 he was appointed Senior Vice President of Market Access in the US. In this role he was responsible for securing formulary access with key payer customers for [Novo Nordisk](/org/novo-nordisk) brands. In March 2017 Mr Langa was appointed senior vice president, head of North America Operations and president of [Novo Nordisk](/org/novo-nordisk) Inc., and in August 2017 Mr Langa was promoted to executive vice president, continuing his responsibilities as head of North America Operations and president of [Novo Nordisk](/org/novo-nordisk) Inc. Mr. Langa represents [Novo Nordisk](/org/novo-nordisk) Inc. on the Board of Directors of the trade association [PhRMA](/org/phrma).

Mr Langa joined [Novo Nordisk](/org/novo-nordisk) from GlaxoSmithKline, where he was the Senior Director of Payer Marketing. Prior to GlaxoSmithKline Mr Langa spent the majority of his career at Johnson and Johnson, where he held various roles of increasing responsibility within Managed Markets, Sales Leadership and Marketing.

Doug Langa

Karsten Munk Knudsen joined [Novo Nordisk](/org/novo-nordisk) in 1999 as a business analyst in NNIT A/S, previously a subsidiary of [Novo Nordisk](/org/novo-nordisk), and has since held finance positions of growing size and complexity throughout the [Novo Nordisk](/org/novo-nordisk) value chain. From 2010 to 2014 Mr Knudsen was corporate vice president for Finance & IT at [Novo Nordisk](/org/novo-nordisk) Inc. in the US and in 2014 he was appointed senior vice president of Corporate Finance in [Novo Nordisk](/org/novo-nordisk). In February 2018 Mr Knudsen was promoted to executive vice president and chief financial officer. In April 2019 Mr Knudsen assumed further responsibilities as his area was expanded to cover Finance, Legal & Procurement.

Mr Knudsen serves as chair of the board of [NNE A/S](/org/nne-as), Denmark.

Karsten Munk Knudsen

Mr Wulff joined [Novo Nordisk](/org/novo-nordisk) in 1998 in the logistic and planning function. From 2001 to 2008 he held different managerial roles within [Novo Nordisk](/org/novo-nordisk)’s manufacturing organisation, Product Supply, before being appointed senior vice president of Diabetes API in Product Supply, Denmark. In 2012 Mr Wulff was appointed senior vice president of the worldwide division Diabetes Finished Products. In 2013 he was promoted senior vice president of Product Supply globally. In April 2015 Mr Wulff was promoted executive vice president and in 2019 with an expanded responsibility covering Global IT and Quality Assurance.

Mr Wulff is chair of the board of [Novo Nordisk](/org/novo-nordisk) Pharmatech A/S and a member of the board of Ambu A/S, both in Denmark.


Henrik Wulff

Lars Fruergaard Jørgensen joined Novo Nordisk in 1991 as an economist in Health Care, Economy & Planning and has over the years completed overseas postings in the Netherlands, the US and Japan. In 2004 he was appointed senior vice president for IT & Corporate Development. In January 2013 he was appointed executive vice president and chief information officer assuming responsibility for IT, Quality & Corporate Development. In November 2014 he took over the responsibilities for Corporate People & Organisation and Business Assurance and became chief of staff. Mr Jørgensen was appointed president and chief executive officer in January 2017.

Mr Jørgensen serves as vice-chair of the supervisory board and member of the nomination committee of Carlsberg A/S.

Mr Jørgensen has an MSc in Finance and Business Administration from Aarhus School of Business, Aarhus University, Denmark, from 1991.

Mr Jørgensen is a Danish national, born November 1966.

Lars Fruergaard Jørgensen

Professor Marcus Schindler, PhD, is Senior Vice President and Head of Global Drug Discovery at [Novo Nordisk](/org/novo-nordisk) A/S. He is accountable for all of [Novo Nordisk](/org/novo-nordisk)’s Research activities across all of [Novo Nordisk](/org/novo-nordisk)’s Therapeutic Areas (Diabetes, Obesity, NASH, Rare blood disorders, Rare endocrine disorders, Chronic Kidney and Cardiovascular Disease). In addition, he is responsible for identifying, establishing and maintaining all external partnerships and collaborations up to and including Clinical Proof of Concept within these therapy areas. He also represents [Novo Nordisk](/org/novo-nordisk) as Supervisory Board Member of Innate Pharma (France).

Marcus has close to 20 years of experience in leadership roles in the pharmaceutical industry, working both in international large pharma and biotechnology companies including Astra Zeneca (Sweden), [Boehringer Ingelheim](/org/boehringer-ingelheim) (Germany) and (OSI) Prosidion (UK).

Marcus Schindler received his PhD in Pharmacology from the [University of Cambridge](/org/university-of-cambridge) and holds a position as adjunct Professor of Pharmacology at the University of Gothenburg. He has co-/authored 50+ peerreviewed research papers and is an inventor of 25 international patent applications

Marcus Schindler

Frederikke Thomsen

Christina Law is a Member of the Board of Directors and member of the Audit Committee.

Christina Law

Liselotte Hyveled is a Member of the Board of Directors (employee representative) and member of the R&D Committee.

Liselotte Hyveled

Elisabeth Dahl Christensen is a Member of the Board of Directors (employee representative) and member of the Remuneration Committee.

Elisabeth Dahl Christensen

Louise Bondo

Anette Spahn Klausen

Jesper Bøving

Stephen Gough is currently the Global Chief Medical Officer at [Novo Nordisk](/org/novo-nordisk). Prior to this, they were a Senior Principal Clinical Scientist at [Novo Nordisk](/org/novo-nordisk) from October 2015 to January 2020. From February 2010 to September 2015, they were a Professor of Diabetes at the [University of Oxford](/org/university-of-oxford). From August 1996 to May 2010, they were a Professor of Medicine at the [University of Birmingham](/org/university-of-birmingham).

Stephen Gough attended the [University of Leeds](/org/university-of-leeds), where they studied medicine and earned their MBChB. Stephen then attended Lancaster Royal Grammar School.

Stephen Gough reports to Martin Holst Lange, EVP, Head of Development. Stephen Gough works with Kenneth Strømdahl - Senior Vice President, Device R&D, Robin Evers - Senior Vice President.

Stephen Gough

Mads Tang-Christensen is the current CVP, Therapeutic Area Head Global Obesity & Liver Disease Research at [Novo Nordisk](/org/novo-nordisk). Prior to this, they were the CEO of gubra from October 2008 to January 2010, and before that, they were a læge at ccbr from January 1999 to December 2001. Mads has also been with [Novo Nordisk](/org/novo-nordisk) in various capacities from 1996 to 1999, including as a PhD student from January 1996 to December 1999.

Mads Tang-Christensen has an MD and a PhD in integrative neuroendocrinology from Københavns Universitet - University of Copenhagen. Mads also attended Odsherreds Gymnasium and Toshkent Avtomobil - Yo'llar Instituti.

Mads Tang-Christensen reports to Karin Conde-Knape, Senior Vice President, Global Drug Discovery.

Mads Tang-Christensen

Lars Fogh Iversen

Henrik Poulsen

Ole Mølskov Bech is a senior vice president at Novo Nordisk Japan. Ole has been with the company for over 20 years and is responsible for the company's operations in Japan.

Ole Mølskov Bech is a Danish physician who earned their M.D. from Københavns Universitet - University of Copenhagen. Ole specialized in medicine and has worked as a physician for many years.

Their manager is Maziar Mike Doustdar, Executive Vice President, International Operations. Ole Mølskov Bech works with Frederik Kier - Senior Vice President, North West Europe, Jesper Wenzel Larsen - Senior Vice President & General Manager of Germany, and Andrzej Popkowski - Senior Vice President, LATAM.

Ole Mølskov Bech

Sebnem Avşar Tuna

Julie Rehoff Hansen

Peter Bøggild is the Senior Vice President of Business Finance at [Novo Nordisk](/org/novo-nordisk). Peter has been with the company since 2005, and in their current position since 2012. Prior to that, they were the Director of Operations Finance, and before that, the Director of Finance & Operations for [Novo Nordisk](/org/novo-nordisk) Turkey.

Bøggild is a key member of [Novo Nordisk](/org/novo-nordisk)'s management team, and has been instrumental in the company's success in recent years. Peter has a deep understanding of the business, and their financial acumen has helped [Novo Nordisk](/org/novo-nordisk) to meet its financial targets. In addition, their project management skills have been invaluable in ensuring the successful implementation of global projects such as the "Sales & Marketing Transparency Project".

Bøggild is a dedicated and hard-working employee, who is always looking for ways to improve the company's bottom line. Peter is an excellent communicator and team player, and is respected by their colleagues for their knowledge and experience.

Peter Bøggild has a Foundation for Business Leadership from IMD, an Advanced Strategic Management from ASM, an MSc in Auditing and Accounting from [Aalborg University](/org/aalborg-universitet), and a Graduate Diploma in Business Administration in Financial and Accounting Management from [Aalborg University](/org/aalborg-universitet). Peter also has certification from IMD in Advanced Strategic Management and certification from IMD business school in IMD FBL.

Some of their coworkers include Tomas Haagen - Group General Counsel & Senior Vice President, Kim Bundegaard - Senior Vice President. Peter Bøggild reports to Karsten Munk Knudsen, Executive Vice President, Chief Financial Officer.

Peter Bøggild

Tomas Haagen is the current Group General Counsel & Senior Vice President at [Novo Nordisk](/org/novo-nordisk). Prior to this, they were the Chairman of the Board at Deloitte Fonden from June 2011 to March 2020. From January 1999 to September 2018, they were a Partner, Corporate/M&A at [Gorrissen Federspiel](/org/gorrissen-federspiel). From September 1994 to March 1995, they were a Foreign Associate at [Slaughter and May](/org/slaughter-and-may).

Tomas Haagen is a lawyer who graduated from Aarhus University.

Their manager is Karsten Munk Knudsen, Executive Vice President, Chief Financial Officer. They work with Peter Bøggild - Senior Vice President, Business Finance, Kim Bundegaard - Senior Vice President.

Tomas Haagen

Mille Borchorst

Ms Sylvest joined [Novo Nordisk](/org/novo-nordisk) in 1996 as trainee. From 1997 to 2008 Ms Sylvest had roles in headquarters and regions within pricing, health economics, marketing and sales effectiveness. In 2003, she was appointed vice president of sales and marketing effectiveness in Region Europe. From 2008 to 2015 Ms Sylvest headed up affiliates and business areas of growing size and complexity in Europe and Asia and in 2013 she was also appointed corporate vice president. In August 2015 Ms Sylvest was appointed senior vice president and general manager of [Novo Nordisk](/org/novo-nordisk)’s Region China. In this role she was responsible for the company’s activities in China, Taiwan and Hong Kong. In October 2017 Ms Sylvest was promoted to executive vice president.

Ms Sylvest serves as member of the board of Danish Crown A/S, and Vice chairman and member of the board of the World Diabetes Foundation, both in Denmark.

Camilla Sylvest

Susanne Hundsbæk-Pedersen joined [Novo Nordisk](/org/novo-nordisk) in 2002, and has held positions as head of Procurement, Divisional CFO for Global Product Supply and IT prior to her current role. She is responsible for the global end-to-end Supply Chain Management operations, ranging from procurement across manufacturing planning and the distribution to global affiliates.

Her organization bridges efforts in R&D with Operations in order to ensure efficient ramp-up and optimization of the device manufacturing processes and the packaging operation. This includes precision plastic moulding operation and needle manufacturing operation with a global reach across US, Brazil, Europe and China.Novo Nordisk Contract manufacturing set-up and local manufacturing resides within Susanne’s area of responsibility which includes factories in Japan, Russia, Algeria and a number of partnership set-ups in multiple countries. Susanne is a member on the Supply Chain Advisory Group to the Bill and Melinda Gates Foundation.

Susanne Hundsbæk-Pedersen

Martin Mackay

Andreas Fibig

Sylvie Grégoire

Laurence Debroux

Kasim Kutay

Mette Bøjer Jensen

Jeppe Christiansen

Mr Lund is Chair of the Board of BP p.l.c. and serves as operating advisor to [Clayton Dubilier & Rice](/org/cdr), US. 

Helge Lund served as chief executive of BG Group plc, UK, the global oil and gas company, from 2015 to 2016 when the company was acquired by Shell. Prior to that Mr Lund served as president and CEO of Equinor ASA (formerly known as Statoil ASA), Norway, from 2004 to 2014. From 2002 to 2004 Mr Lund served as president & CEO of Aker Kvaerner ASA, Norway, an industrial conglomerate with operations in oil and gas, engineering and construction, pulp and paper and shipbuilding. Prior to this Mr Lund has also held executive positions in Aker RGI ASA, Norway, an industrial holding company, and Hafslund Nycomed, Norway, an industrial group with business activities in pharmaceuticals and energy.

Mr Lund is also member of the boards of P/F Tjaldur, Faroe Islands, Inkerman Holding AS, Norway, and Belron SA, Luxembourg. Furthermore, Mr Lund is a member of the Board of Trustees of the International Crisis Group.

Mr Lund has an MA in Economics from the Norwegian School of Economics & Business Administration (NHH), Norway, from 1987 and an MBA from [INSEAD](/org/insead), France, from 1991.

From 2014 to 2015 Mr Lund was a member of the Board of Directors of Novo Nordisk A/S and Mr Lund was elected to the Board of Novo Nordisk A/S again in March 2017. In March 2018 he was elected as chair of the Board of Directors and has been re-elected again in March 2019. His term as a board member expires in March 2020.

In March 2019, the Board of Directors of Novo Nordisk A/S assessed that Mr Lund is regarded as an independent board member as defined in Section 3.2.1 of the Recommendations on Corporate Governance designated by Nasdaq Copenhagen.

Mr Lund became a member of the Nomination Committee at Novo Nordisk A/S in March 2017 and Mr Lund became chair of the Nomination Committee in March 2018.

In January 2019, the Board of Directors assessed that the special competences possessed by Mr Lund that are important for the performance of his duties are his extensive executive and board experience in large multinational companies headquartered in Scandinavia within regulated markets and significant financial knowledge.

Mr Lund is a male Norwegian national, born October 1962.

Novo Nordisk

About

Photos

Values

Insider experiences

Org chart

Teams

Jobs

Wires

Similar organizations